AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Genprex Stock Plunges 16.52% Amid Market Concerns
Generated by AI AgentAinvest Pre-Market Radar
Friday, May 30, 2025 7:26 am ET1min read
On May 30, 2025, Genprex's stock experienced a significant drop of 16.52% in pre-market trading, reflecting investor sentiment and potential market concerns.
Genprex, a clinical-stage gene therapy company, has been actively involved in presenting and sharing positive preclinical data on its gene therapy programs. The company's collaborators have presented data on the use of Reqorsa® Gene Therapy for the treatment of lung cancer, highlighting its potential as a therapy for Ras inhibitor-resistant non-small cell lung cancer. Additionally, Genprex's research collaborators have presented positive preclinical data on diabetes gene therapy, showcasing the potential of GPX-002 in addressing both Type 1 and Type 2 diabetes.
Genprex is also set to present the trial design of the Acclaim-3 Phase 1/2 clinical trial evaluating Reqorsa® Gene Therapy in combination with Tecentriq® for the treatment of extensive stage small cell lung cancer at the 2025 ASCO Annual Meeting. This presentation is expected to highlight the company's ongoing efforts in developing innovative therapies for cancer patients.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Metallus shares plunge 6.73% as investor concerns over earnings volatility and sector risks grow
Dec.22 2025
Annexon (ANNX) Surges 7.26% in Pre-Market Trading After S&P Biotechnology Index Inclusion
Dec.22 2025
Aeva Technologies Inc. surges 7.69% on strategic partnership with major automaker
Dec.22 2025
Oracle shares surge 6.63% on OpenAI rebuttal and healthcare contracts
Dec.22 2025
Broadcom Inc. (NASDAQ:AVGO) surges 3.18% on analyst upgrades amid AI growth optimism
Dec.22 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet